9/17/2025
• Posted by Provider Relations
The following sections of the Fidelis Care authorization grids have been updated effective October 1, 2025.
The following codes have been updated on the Medicaid, CHP, Essential Plan, Ambetter Metal-Level Plans, and Medicare Authorization Grids and require prior authorization:
C9305 nipocalimab-aahu (Imaavy)
C9306 telisotuzumab vedotin-tllv (Emrelis)
J0614 treosulfan (Grafapex)
J1370 esomeprazole injection
J1809 fosdenopterin
J3402 remestemcel-l-rknd (Ryoncil)
J3403 Revakinagene taroretcel-lwey (Encelto)
J7173 concizumab-mtci (Alhemo)
J7174 fitusiran (Qflitlia)
J9011 datopotamab deruxtecan-dlnk (Datroway)
Q5154 omalizumab-igec (Omlyclo)
Q5155 aflibercept-jbvf (Yesafili)
Q5156 tocilizumab-anoh (Avtozma)
Q5157 denosumab-bmwo (Stoboclo/Osenvelt)
Q5158 denosumab-bnht (Bomyntra/Conexxence)
Q5159 denosumab-dssb (Ospomyv/Xbryk)
For Medicaid, CHP, Essential Plan, Ambetter Metal-Level Plans, and Medicare, the following codes have been added to the list of drugs that require NCH review:
J9011 datopotamab deruxtecan-dlnk (Datroway)
Q5156 tocilizumab-anoh (Avtozma)
Q5157 denosumab-bmwo (Stoboclo/Osenvelt)
Q5158 denosumab-bnht (Bomyntra/Conexxence)
Q5159 denosumab-dssb (Ospomyv/Xbryk)
Visit:
9/10/2025
• Posted by Fidelis Care
El objetivo de las subvenciones es respaldar los programas de atención preventiva innovadora en comunidades rurales
LONG ISLAND CITY, NY (10 de septiembre de 2025) Fidelis Care, un plan de salud estatal con más de 2.4 millones de miembros en el estado de Nueva York y propiedad de la empresa Centene Corporation, abrió el proceso de presentación de solicitudes para su programa de subvenciones de salud rural de 2025.
9/9/2025
• Posted by Provider Relations
Fidelis Care would like to inform providers of a significant development impacting COVID-19 vaccine access across New York State.
On Friday, Governor Kathy Hochul signed an executive order declaring a disaster emergency to ensure near-universal access to the latest COVID-19 vaccines. This order, effective through October 5, 2025, enables pharmacists to prescribe and administer the 2025–2026 COVID-19 vaccine formulations to patients ages 3 and older.
While the FDA has only approved the latest vaccine formulations for individuals at high risk of severe illness or those aged 65 and older, the executive order allows broader access in anticipation of the upcoming respiratory virus season.
Key Points
9/5/2025
• Posted by Provider Relations
Fidelis Care is pleased to announce that a new Provider Bulletin is now available. The bulletin features updates on important initiatives and the latest news of interest to our provider community.
Articles in this issue:
· Championing Mental Health: Early Intervention is Key
· Important Reminders About HIV Prevention and Testing
· Supporting Maternal Health for Healthy Pregnancies and Babies
· Encourage Preventive Cancer Screenings
· Help Your Patients of All Ages Stay Active!
· Access and Availability Standards
Please download Fidelis Care Provider Bulletin – Volume 11, Issue 3.
To view our Provider Bulletin Library, please visit: Provider Bulletins.
Newer Articles
Older Articles